Literature DB >> 20338255

Recipient B cells are not required for graft-versus-host disease induction.

Catherine Matte-Martone1, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony J Demetris, Jennifer McNiff, Mark J Shlomchik, Warren D Shlomchik.   

Abstract

Recipient antigen presenting cells (APCs) are required for CD8-mediated graft-versus-host disease (GVHD), and have an important and nonredundant role in CD4-mediated GVHD in mouse major histocompatibility complex-matched allogeneic bone marrow transplantation (alloBMT). However, the precise roles of specific recipient APCs-dendritic cells, macrophages, and B cells-are not well defined. If recipient B cells are important APCs they could be depleted with rituximab, an anti-CD20 monoclonal antibody. On the other hand, B cells can downregulate T cell responses, and consequently, B cell depletion could exacerbate GVHD. Patients with B cell lymphomas undergo allogeneic hematopoietic stem cell transplantation (alloSCT) and many are B-cell-deficient because of prior rituximab. We therefore studied the role of recipient B cells in major histocompatibility complex-matched murine models of CD8- and CD4-mediated GVHD by using recipients genetically deficient in B cells and with antibody-mediated depletion of host B cells. In both CD4- and CD8-dependent models, B cell-deficient recipients developed clinical and pathologic GVHD. However, although CD8-mediated GVHD was clinically less severe in hosts genetically deficient in B cells, it was unaffected in anti-CD20-treated recipients. These data indicate that recipient B cells are not important initiators of GVHD, and that efforts to prevent GVHD by APC depletion should focus on other APC subsets. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20338255      PMCID: PMC3135976          DOI: 10.1016/j.bbmt.2010.03.015

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  53 in total

Review 1.  Endogenous antigen presentation by MHC class II molecules.

Authors:  A J Sant
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

2.  Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells.

Authors:  D M Allman; S E Ferguson; V M Lentz; M P Cancro
Journal:  J Immunol       Date:  1993-11-01       Impact factor: 5.422

3.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors:  I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

Review 4.  Processing and presentation of idiotypes to MHC-restricted T cells.

Authors:  B Bogen; S Weiss
Journal:  Int Rev Immunol       Date:  1993       Impact factor: 5.311

5.  Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.

Authors:  Britt E Anderson; Patricia A Taylor; Jennifer M McNiff; Dhanpat Jain; Anthony J Demetris; Angela Panoskaltsis-Mortari; Ann Ager; Bruce R Blazar; Warren D Shlomchik; Mark J Shlomchik
Journal:  Blood       Date:  2008-02-19       Impact factor: 22.113

6.  Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

Authors:  Chang-yun Hu; Daniel Rodriguez-Pinto; Wei Du; Anupama Ahuja; Octavian Henegariu; F Susan Wong; Mark J Shlomchik; Li Wen
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

7.  CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.

Authors:  Catherine Matte-Martone; Jinli Liu; Dhanpat Jain; Jennifer McNiff; Warren D Shlomchik
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

8.  Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells.

Authors:  M Croft; L M Bradley; S L Swain
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

9.  B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo.

Authors:  S Constant; N Schweitzer; J West; P Ranney; K Bottomly
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

10.  Successful T cell priming in B cell-deficient mice.

Authors:  M M Epstein; F Di Rosa; D Jankovic; A Sher; P Matzinger
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

View more
  11 in total

1.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction.

Authors:  Hongmei Li; Anthony J Demetris; Jennifer McNiff; Catherine Matte-Martone; Hung Sheng Tan; David M Rothstein; Fadi G Lakkis; Warren D Shlomchik
Journal:  J Immunol       Date:  2012-03-14       Impact factor: 5.422

Review 3.  Biology of graft-versus-host responses: recent insights.

Authors:  Kelli P MacDonald; Warren D Shlomchik; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2013-01       Impact factor: 5.742

Review 4.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

5.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Authors:  Motoko Koyama; Rachel D Kuns; Stuart D Olver; Neil C Raffelt; Yana A Wilson; Alistair L J Don; Katie E Lineburg; Melody Cheong; Renee J Robb; Kate A Markey; Antiopi Varelias; Bernard Malissen; Günter J Hämmerling; Andrew D Clouston; Christian R Engwerda; Purnima Bhat; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Nat Med       Date:  2011-11-29       Impact factor: 53.440

6.  Host basophils are dispensable for induction of donor T helper 2 cell differentiation and severity of experimental graft-versus-host disease.

Authors:  Isao Tawara; Evelyn Nieves; Chen Liu; Rebecca Evers; Tomomi Toubai; Yaping Sun; Mariem Alrubaie; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-25       Impact factor: 5.742

Review 7.  GVHD prevention: an ounce is better than a pound.

Authors:  Pavan Reddy; Gérard Socié; Corey Cutler; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

8.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

Review 9.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion.

Authors:  L H Laws; C E Parker; G Cherala; Y Koguchi; A Waisman; M K Slifka; M H Oberbarnscheidt; J S Obhrai; M Y Yeung; L V Riella
Journal:  Am J Transplant       Date:  2016-07-12       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.